Anzu Partners Launches Third Venture Capital Fund For Breakthrough Industrial And Life Science Technologies
Anzu held its first closing of a third venture fund and has $130M in commitments to date
Anzu Partners, an investment firm that focuses on early stage industrial and life science technology companies, announced that its third venture fund has $130M in commitments to date toward a $300M target size.
Anzu’s Fund III will invest in early-stage breakthrough technology companies that can shape and enable high growth sectors that are essential to prosperity, productivity, and sustainability. The fund’s investors include public and private institutions, single and multifamily offices, and individuals across the U.S. and overseas.
Since its founding in 2014, Anzu Partners has grown into a robust investment firm with over 50 team members, and approximately $935M in strategic assets across several funds and strategies, including two existing oversubscribed venture funds (Fund 1 $128M, Fund II $190M), a $425M Special Purpose Acquisition Company (“SPAC”), and a series of special purpose vehicles. Since the close of Fund II, Debrah Herman, Dr. John Ho, and most recently, international investment banker William H. Strong, have joined Managing Partners David Michael, David Seldin, and Whitney Haring-Smith on Anzu’s leadership team.
Recommended AI News: Thrive Global Teams Up With Zoom To Launch Thrive Reset App
Anzu will build on its existing portfolio of over 25 companies with the launch of Fund III. The firm continues to focus on identifying and supporting teams pioneering innovations that address major global challenges ranging from next-generation manufacturing to therapy discovery. For example:
- 6K has developed an advanced materials production platform to disrupt traditional solid-state and chemical synthesis production processes
- Niron Magnetics has developed rare-earth free magnets for a more sustainable electric economy
- InterVenn Biosciences has developed a proprietary glycoproteomic platform that enables a powerful new class of cancer diagnostics based on glycobiology
“Innovations in life sciences and industrial technologies continue to proliferate since the launch of our first two funds, and we see an even greater opportunity to work with early-stage companies and commercialize their scientific breakthroughs,” said David Michael, Managing Partner, Anzu Partners. “Not only do we provide capital, we also utilize our technically-oriented team of investment and operational professionals to offer support on financial management, operations, talent development, global connectivity, strategy, and more, to truly serve as a partner. We are excited about the future of Anzu Partners and our portfolio as we begin to explore the already active pipeline of opportunities for Fund III.”